Limited Offer
Coronavirus Drug Discovery
Volume 3: Druggable Targets and In Silico Update
- 1st Edition - July 6, 2022
- Editor: Chukwuebuka Egbuna
- Language: English
- Paperback ISBN:9 7 8 - 0 - 3 2 3 - 9 5 5 7 8 - 2
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 5 5 7 9 - 9
Coronavirus Drug Discovery, Volume Three: Druggable Targets and In Silico Update presents comprehensive information on drug discovery against COVID-19. Chapters in Part One of th… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteCoronavirus Drug Discovery, Volume Three: Druggable Targets and In Silico Update presents comprehensive information on drug discovery against COVID-19. Chapters in Part One of this volume describe the various druggable targets and associated signaling pathways for effective targeting of SARS-CoV-2. In Part Two, chapters discuss the various computational approaches and in silico studies against SARS-CoV-2. Written by global team of experts, this book is an excellent resource that will be extremely useful to drug developers, medicinal chemists, pharmaceutical companies in R&D, research institutes in both academia and industry, and the National Library of Medicines and Health.
In addition, agencies such as the National Institutes of Health, Centers for Disease Control and Prevention, World Health Organization, European Medicines Agency, the US Food and Drug Administration, and all others involved in drug discovery against COVID-19 will find this book useful.
- Discusses the pathogenic mechanisms of SARS-CoV-2 and druggable targets
- Reviews the various signaling pathways associated with SAR-CoV-2 as possible druggable targets
- Presents computational approaches and in silico studies against SARS-CoV-2
- Cover image
- Title page
- Table of Contents
- Copyright
- List of contributors
- Part I. Druggable targets and signaling pathways
- Chapter 1. SARS-CoV-2 genome sequencing and promising druggable targets
- 1.1. Introduction
- 1.2. Genome sequencing of SARS-CoV-2: outcomes and predictions
- 1.3. Druggable targets
- 1.4. Future projections
- 1.5. Conclusion
- Chapter 2. Signaling pathways implicated in SARS-CoV-2 infection: key drug targets for human coronaviruses and related viral infections
- 2.1. Introduction
- 2.2. Reservoir animals and their signaling cues for viral disease alleviation
- 2.3. Signaling pathways of SARS-CoV pathogenesis in humans
- 2.4. Drug-target implications conceived from SARS signaling
- 2.5. Future projections
- 2.6. Conclusion
- Chapter 3. Roles of membrane lipids and lipid synthesis inhibitors in the propagation of coronavirus disease
- 3.1. Introduction
- Chapter 4. Potential drugs in SARS-CoV-2 treatment: key features and mechanisms of actions
- 4.1. Introduction
- 4.2. Clinical symptoms
- 4.3. Caring for chronically ill COVID-19 patients
- 4.4. Antiviral drugs for COVID-19 treatment
- 4.5. Future projections
- 4.6. Conclusion
- Chapter 5. Natural drugs for the treatment of severe acute respiratory syndrome coronaviruses infections (SARS-CoV and COVID-19): a complete review of in vitro, in vivo, in silico, and clinical studies
- 5.1. Introduction
- 5.2. Methods for evaluating antiviral activities of natural bioactive molecules against SARS coronaviruses
- 5.3. Treatment of SARS coronavirus infections with natural products from plants origin
- 5.4. Isolated molecules from plants for treatment of SARS coronavirus infections
- 5.5. Treatment of SARS coronavirus infections by microbial, animal, and human bioactive molecules
- 5.6. In vivo and clinical studies of natural medicines for the treatment of SARS coronavirus infections
- 5.7. Evaluation of in silico antiviral activity of natural medicines for the treatment of COVID-19 infections
- 5.8. Relationship between of SARS-CoV and COVID-19 treatment using natural drugs
- 5.9. Conclusion and perspectives
- Chapter 6. Plants with potent antiviral properties
- 6.1. Introduction
- 6.2. Antiviral medicinal plants and phytochemicals
- 6.3. Antiviral: a herbal approach
- 6.4. Antiviral activity of medicinal and herbal plants against selected viruses
- 6.5. Future projections
- 6.6. Conclusion
- Chapter 7. Herbal-based resources against exanthematous viral infections and other viral diseases
- 7.1. Introduction
- 7.2. Viruses associated with cutaneous manifestations of skin eruptions
- 7.3. Medicinal plants and bioactive compounds in new drug discovery
- 7.4. Future prospectives
- 7.5. Conclusions
- Chapter 8. Dietary polyphenols as therapeutic agents to combat COVID-19
- 8.1. Introduction
- 8.2. Significance of dietary polyphenols as antiviral agents
- 8.3. Molecular targets and mechanism of action of anti-SARS-CoV-2 dietary polyphenols
- 8.4. Bioavailability and toxicity of anti-COVID-19 dietary polyphenols
- 8.5. Anti-SARS-CoV-2 polyphenol contents in dietary foods and their recommended daily intake
- 8.6. Conclusions and future recommendations
- Part II. Computational approaches
- Chapter 9. Computational demonstration of cheminformatics and machine learning in coronavirus drug discovery
- 9.1. Introduction
- 9.2. The development of potential therapeutics
- 9.3. Demonstration of the use of computational tools in COVID-19 drug discovery
- 9.4. Findings from hands-on experiment
- 9.5. Future perspectives
- 9.6. Conclusion
- Chapter 10. In silico approaches in drug discovery for SARS-CoV-2
- 10.1. Introduction
- 10.2. Ongoing clinical trials
- 10.3. Traditional drug discovery process
- 10.4. In silico drug design
- 10.5. In silico methods of drug discovery
- 10.6. Potential drug targets of SARS-CoV-2 proteins via in silico approaches
- 10.7. In silico studies for SARS-CoV-2 drug discoveries
- 10.8. Future projections
- 10.9. Conclusion
- Chapter 11. Application of molecular docking and dynamics tools in SARS-CoV-2 drug design: ligand–protein interaction studies
- 11.1. Introduction
- 11.2. Pathophysiology of SARS-CoV-2
- 11.3. Role of structural proteins
- 11.4. Treatment
- 11.5. Prevention of infection
- 11.6. What is bioinformatics?
- 11.7. Future projections
- 11.8. Conclusion
- Chapter 12. Molecular dynamic simulation with protein and detection of repurposable drugs for COVID-19
- 12.1. Introduction
- 12.2. Molecular docking
- 12.3. Molecular dynamics (MD) analysis
- 12.4. Binding pockets prediction
- 12.5. Structure-based virtual screening
- 12.6. Docking results for the isolated virus S-protein host recognition domain
- 12.7. The network of the protein's dynamic components
- 12.8. Preparation of ligands
- 12.9. Drug repurposing for COVID-19
- 12.10. Future projections
- 12.11. Conclusion
- Chapter 13. Computation-guided inhibitor screening against the nucelocapsid of SARS-CoV-2
- 13.1. Introduction
- 13.2. Case study
- 13.3. Results and discussion
- 13.4. Future projection
- 13.5. Conclusion
- Chapter 14. In silico insight into the interaction of 4-aminoquinolines with selected SARS-CoV-2 structural and nonstructural proteins
- 14.1. Introduction
- 14.2. Materials and methods
- 14.3. Results and discussion
- 14.4. Conclusion
- Chapter 15. In silico evaluation of anti-SARS-CoV-2 activity of Punica granatum L. phytochemicals
- 15.1. Introduction
- 15.2. Materials and methods
- 15.3. Result and discussion
- 15.4. Future projections
- 15.5. Conclusion
- Chapter 16. In silico investigation and identification of bioactive compounds from medicinal plants as potential inhibitors against SARS-CoV-2 cellular entry
- 16.1. Introduction
- 16.2. Materials and methods
- 16.3. Results and discussion
- 16.4. Future projections
- 16.5. Conclusion
- Index
- No. of pages: 406
- Language: English
- Edition: 1
- Published: July 6, 2022
- Imprint: Elsevier
- Paperback ISBN: 9780323955782
- eBook ISBN: 9780323955799
CE
Chukwuebuka Egbuna
Chukwuebuka Egbuna (PhD) is a chartered chemist and academic researcher. He is a member of the Institute of Chartered Chemists of Nigeria (ICCON), the Nigerian Society of Biochemistry and Molecular Biology (NSBMB), and the Royal Society of Chemistry (RSC) (United Kingdom). Dr. Egbuna is the founder and editor of the Elsevier book series on Drug Discovery Update. The series includes books, monographs, and edited collections from all areas of drug discovery including emerging therapeutic claims for the treatment of diseases. He has published research articles in many international journals of repute and is ranked among the top 500 Nigerian scientists in SciVal/SCOPUS. He has edited more than 25 books with Elsevier, Springer, Wiley, and Taylor & Francis. His most recent book is the three volume Coronavirus Drug Discovery, published by Elsevier. Dr. Egbuna is the founder and the publishing director of IPS Intelligentsia Publishing Services.